ClinicalTrials.gg
Enrolling by invitationNCT07352696PsA-HIITUpdated Oct 23, 2026

Combined High-Intensity Aerobic Training and Resistance Training in Psoriatic Arthritis

An interventional study of Exercise program in Psoriatic Arthritis, sponsored by Vastra Gotaland Region. Enrolling by invitation at 2 sites in Sweden. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now Enrolling by invitationStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Arthritis, Psoriatic with a site in Sweden — 3 open to participants now, 8 under way, 2 of them phase 3. Arthritis, Psoriatic · Sweden.

Planned enrollment
12th of 16
88 · median 276
Started
2026
the only one that year
No phase
4 of 24
1 open now
Registered
22nd of 24
by date
Lead sponsor
5 of 24
Vastra Gotaland Region

Among the 24 studies in Arthritis, Psoriatic with a site in Sweden, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 4 with no phase, and was the 22nd registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 24 studies in Arthritis, Psoriatic with a site in Sweden are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Arthritis, Psoriatic with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this randomised controlled trial is to evaluate the effects of a 12-week intervention comprising high-intensity interval aerobic training and strength training on cardiovascular function, metabolic health profile and inflammation in patients with Psoriatic arthritis. A secondary goal is to assess the intervention´s impact on physical fitness, pain, fatigue, and health-related quality of life, and to explore long-term maintenance of exercise following completion of the intervention. We hypothesize that 12 weeks of combined high-intensity interval aerobic training and strength training will improve cardiometabolic health, inflammation, and enhance physical fitness, fatigue, pain and quality of life in Psoriatic arthritis.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Psoriatic arthritis disease according to the CASPAR (Classification Criteria for Psoriatic Arthritis) criteria
  • Age range 18-65 years
  • Stable medication on anti- rheumatic drugs for >3 months prior to inclusion and throughout the first 3 months of the study

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular disease
  • Severe hypertension
  • Diabetes type I
  • or other severe pulmonary diseases
  • Arthroplasty of large joints, lower extremities
  • Severe functional impairment precluding participation in high-intensity aerobic exercise
  • Inability to perform a cardiopulmonary exercise testing (CPET)
  • Pregnancy
  • ≥35 kg/m²
  • Ongoing or planned initiation (within 3 months) of structured weight reduction therapy, pharmacological obesity treatment, or bariatric bypass surgery
  • Already participating in regular exercise at high intensity (BORG ≥15) for >1 hour/ week during the past 6 months
  • Inability to understand and read Swedish
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Exercise group

    Cardiorespiratory and strength training, 2-3 sessions per week for a total of 12 weeks.

    Behavioral: Exercise program

  • No intervention
    Control group

    Care as usual, plus individualized counseling for health-promoting physical activity

Interventions

  • BehavioralExercise program

    The exercise program includes two supervised sessions per week combining high-intensity interval training and strength training, plus one additional non-supervised aerobic session. The target of the high intensity intervals is 90%-95% of heart rate maximum. The strength training of major muscle groups includes 2-3 sets of 8-10 repetitions.

06

What researchers measure

Primary outcomes

  1. Cardiopulmonary function

    Change in maximum oxygen uptake (VO2ml/min/kg). Higher value indicate better cardiorespiratory capacity.

    Time frame: Baseline and 3 month

  2. Cardiopulmonary function

    Change in maximum oxygen uptake (VO2ml/min/kg). Higher value indicate better cardiorespiratory capacity)

    Time frame: Baseline and 9 month

Secondary outcomes

  1. Waist circumference

    Change in waist circumference (cm) measured with a tape measure midway between the lower rib and iliac crest. A waist measurement of 80 centimeters or more for women and 94 centimeters or more for men indicate increased risk for diseases related to overweight.

    Time frame: Baseline and 3 months

  2. Waist circumference

    Change in waist circumference (cm) measured with a tape measure midway between the lower rib and iliac crest. A waist measurement of 80 centimeters or more for women and 94 centimeters or more for men indicate increased risk for diseases related to overweight.

    Time frame: Baseline and 9 months

  3. Body mass index (BMI)

    Change in Body Mass Index (BMI). Weight and height will be combined to report BMI (kg/m2). A higher score indicate higher relative weight.

    Time frame: Baseline and 3 months

  4. Body mass index (BMI)

    Change in Body Mass Index (BMI). Weight and height will be combined to report BMI (kg/m2). A higher score indicate higher relative weight.

    Time frame: Baseline and 9 months

  5. Body composition

    Change in total leanmass (%) and fatmass (%) assessed with Bioelectrical Impedance Analysis. Higher value indicate higher total leanmass and fatmass

    Time frame: Baseline and 3 months

  6. Body composition

    Change in total leanmass (%) and fatmass (%) assessed with Bioelectrical Impedance Analysis. Higher value indicate higher total leanmass and fatmass

    Time frame: Baseline and 9 months

  7. Triglycerides

    Change in triglycerides (mmol/L)

    Time frame: Baseline and 3 months

  8. Triglycerides

    Change in triglycerides (mmol/L)

    Time frame: Baseline and 9 months

  9. High-density lipoprotein cholesterol (HDL-C)

    Change in high-density lipoprotein cholesterol (HDL-C) (mmol/L)

    Time frame: Baseline and 3 months

  10. High-density lipoprotein cholesterol (HDL-C)

    Change in high-density lipoprotein cholesterol (HDL-C) (mmol/L)

    Time frame: Baseline and 9 months

  11. Low-density lipoprotein cholesterol (LDL-C)

    Change in low-density lipoprotein cholesterol (LDL-C) (mmol/L)

    Time frame: Baseline and 3 months

  12. Low-density lipoprotein cholesterol (LDL-C)

    Change in low-density lipoprotein cholesterol (LDL-C) (mmol/L)

    Time frame: Baseline and 9 months

  13. Total cholesterol

    Change in total cholesterol (mmol/L)

    Time frame: Baseline and 3 months

  14. Total cholesterol

    Change in total cholesterol (mmol/L)

    Time frame: Baseline and 9 months

  15. Glycosylation level of hemoglobin (HbA1c)

    Glycosylation level of hemoglobin (HbA1c) (mmol/mol)

    Time frame: Baseline and 3 months

  16. Glycosylation level of hemoglobin (HbA1c)

    Glycosylation level of hemoglobin (HbA1c) (mmol/mol)

    Time frame: Baseline and 9 months

  17. Homeostatic model assessment of insulin resistance (HOMA IR)

    Measure of insulin resistance (fasting glucose (mmol/L) and fasting insulin (mIU/ L) will be combined to report Homeostatic model assessment of insulin resistance (HOMA IR).

    Time frame: Baseline and 3 monhts

  18. Homeostatic model assessment of insulin resistance (HOMA IR)

    Measure of insulin resistance (fasting glucose (mmol/L) and fasting insulin (mIU/ L) will be combined to report Homeostatic model assessment of insulin resistance (HOMA IR).

    Time frame: Baseline and 9 months

  19. Erythrocyte Sedimentation Rate (ESR)

    Change in level of erytrocyte rate (ESR) (mm/h). Higher score indicate higher degree of inflammation.

    Time frame: Baseline and 3 months

  20. Erythrocyte Sedimentation Rate (ESR)

    Change in level of erytrocyte rate (ESR) (mm/h). Higher score indicate higher degree of inflammation.

    Time frame: Baseline and 9 months

  21. C-Reactive Protein (CRP)

    Change in level of of high sensitivity CRP (mg/L). Higher score indicate higher inflammation.

    Time frame: Baseline and 3 months

  22. C-Reactive Protein (CRP)

    Change in level of of high sensitivity CRP (mg/L). Higher score indicate higher inflammation.

    Time frame: Baseline and 9 months

  23. Cytokine levels

    Change in inflammatory cytokines such as Interleukin-6 (pg/mL), interleukin-10 (pg/mL), tumour necrosis factor-alpha (pg/mL).

    Time frame: Baseline and 3 months

  24. Disease activity

    Change in Disease Activity index for PSoriatic Arthritis (DAPSA) score. Calculated by summing 66/68 joints (swollen, tender), patient global assessment (VAS), pain (VAS)and CRP). A higher value indicates a higher disease activity. (Minimum: 0=no disease activity, \>28= high disease activity).

    Time frame: Baseline and 3 months

  25. Disease activity

    Change in Disease Activity index for PSoriatic Arthritis (DAPSA) score. Calculated by summing 66/68 joints (swollen, tender), patient global assessment (VAS), pain (VAS)and CRP). A higher value indicates a higher disease activity. (Minimum: 0=no disease activity, \>28= high disease activity).

    Time frame: Baseline and 9 months

  26. Muscle function lower extremities

    Change in the one minute sit-to-stand test (STS). Higher numbers of complete rises indicate better muscle function in lower extremities.

    Time frame: Baseline and 3 months

  27. Muscle function lower extremities

    Change in the one minute sit-to-stand test (STS). Higher numbers of complete rises indicate better muscle function in lower extremities.

    Time frame: Baseline and 9 months

  28. Handgrip strength

    Change in grip strength measured with a dynamometer (newton). Higher value indicate better grip strength.

    Time frame: Baseline and 3 months

  29. Handgrip strength

    Change in grip strength measured with a dynamometer (newton). Higher value indicate better grip strength.

    Time frame: Baseline and 9 months

  30. Activity limitations

    Change in Health Assessment Questionnaire (HAQ) (0-3). A higher score indicates more activity limitations

    Time frame: Baseline and 3 months

  31. Activity limitations

    Change in Health Assessment Questionnaire (HAQ) (0-3). A higher score indicates more activity limitations.

    Time frame: Baseline and 9 months

  32. Physical function

    Change in the Bath Ankylosing Spondylitis Functional Index (BASFI) (0-10). Higher score indicate more physical limitations

    Time frame: Baseline and 3 months

  33. Physical function

    Change in the Bath Ankylosing Spondylitis Functional Index (BASFI) (0-10). Higher score indicate more physical limitations

    Time frame: Baseline and 9 months

  34. Physical activity

    Change in self-reported weekly physical activity assessed with the International Physical Activity Questionnaire (IPAQ)-Short Form. Time spent in low, moderate, and vigorous activity is summed within each intensity category. (According to WHO guidelines, ≥150 minutes of moderate or ≥75 minutes of vigorous activity per week qualifies as health-enhancing physical activity).

    Time frame: Baseline and 3 months

  35. Physical activity

    Change in self-reported weekly physical activity assessed with the International Physical Activity Questionnaire (IPAQ)-Short Form. Time spent in low, moderate, and vigorous activity is summed within each intensity category. (According to WHO guidelines, ≥150 minutes of moderate or ≥75 minutes of vigorous activity per week qualifies as health-enhancing physical activity).

    Time frame: Baseline and 9 months

  36. Attitude to exercise

    Change in exercise believe assessed with the Exercise Health Beliefs questionnaire (20-100), Higher score represents stronger exercise beliefs.

    Time frame: Baseline and 3 months

  37. Attitude to exercise

    Change in exercise believe assessed with the Exercise Health Beliefs questionnaire (20-100), Higher score represents stronger exercise beliefs.

    Time frame: Baseline and 9 months

  38. Emotional experience of exercise

    Change in the Physical Activity Enjoyment Scale (PACES) (18-126). Higher score indicate higher degreee of enjoyment and pleasure related to exercising.

    Time frame: Baseline and 3 months

  39. Emotional experience of exercise

    Change in the Physical Activity Enjoyment Scale (PACES) (18-126). Higher score indicate higher degreee of enjoyment and pleasure related to exercising.

    Time frame: Baseline and 9 months

  40. Sleep quality

    Change in Pittsburgh Sleep Quality Index (PSQI) (0-21), Higher score indicate worse sleep quality.

    Time frame: Baseline and 3 months

  41. Sleep quality

    Change in Pittsburgh Sleep Quality Index (PSQI) (0-21), Higher score indicate worse sleep quality.

    Time frame: Baseline and 9 months

  42. Fatigue

    Change in The Multiple Fatigue Inventory (MFI-20), 4-20 for each subscale, Higher score indicates a higher degree of fatigue.

    Time frame: Baseline and 3 months

  43. Fatigue

    Change in The Multiple Fatigue Inventory (MFI-20), 4-20 for each subscale, Higher score indicates a higher degree of fatigue

    Time frame: Baseline and 9 months

  44. Pain intensity

    Visual Analogue Scale (VAS) (0-100), Higher score indicate worse pain.

    Time frame: Baseline and 3 months

  45. Pain intensity

    Visual Analogue Scale (VAS) (0-100), Higher score indicate worse pain.

    Time frame: Baseline and 9 months

  46. Global health

    Change in Visual Analogue Scale (VAS) (0-100), Higher score indicate worse health

    Time frame: Baseline and 3 months

  47. Global health

    Change in Visual Analogue Scale (VAS) (0-100), Higher score indicate worse health

    Time frame: Baseline and 9 months

  48. Health related quality of life

    Change in the 36-item Short Form Health Survey (SF-36) questionnare (0-100). A higher score indicate better health related quality of life

    Time frame: Baseline and 3 months

  49. Health related quality of life

    Change in the 36-item Short Form Health Survey (SF-36) questionnare (0-100). A higher score indicate better health related quality of life

    Time frame: Baseline and 9 months

  50. The impact of the disease on quality of life

    Change in the Dermatology Life Quality Index (DLQI) (0-30). Higher score indicate worse impairment

    Time frame: Baseline and 3 months

  51. The impact of the disease on quality of life

    Change in the Dermatology Life Quality Index (DLQI) (0-30). Higher score indicate worse impairment

    Time frame: Baseline and 9 months

  52. Mental health

    Change in the Hospital and Anxiety Depression Scale (HADS) for anxiety and depression (0-21). A higher score refers to a higher degree of distress.

    Time frame: Baseline and 3 months

  53. Mental health

    Change in the Hospital and Anxiety Depression Scale (HADS) for anxiety and depression (0-21). A higher score refers to a higher degree of distress.

    Time frame: Baseline and 9 months

  54. Disease related symptoms

    Patient Global Impression of Change (PGIC) scale (0-7) to adress changes in symtoms. Rating from very much improved (7) to very much worse (1).

    Time frame: Baseline and 3 months

  55. Disease related symptoms

    Patient Global Impression of Change (PGIC) scale (0-7) to adress changes in symtoms. Rating from very much improved (7) to very much worse (1).

    Time frame: Baseline and 9 months

  56. Enthesites

    Change in the Entesiter MASES entesit index. Palpation of 13 body sites for tenderness. (0= no tenderness, 1= tenderness presented) Higher scores indicate more widespread/tender enthesitis.

    Time frame: Baseline and 3 months

  57. Enthesites

    Change in the Entesiter MASES entesit index. Palpation of 13 body sites for tenderness. (0= no tenderness, 1= tenderness presented). Higher scores indicate more widespread/tender enthesitis.

    Time frame: Baseline and 9 months

  58. Skin involvement

    Skin involvement evaluated using the Body surface area (BSA), percentage of total body surface affected by lesions.

    Time frame: Baseline and 3 months

  59. Skin involvement

    Skin involvement evaluated using the Body surface area (BSA), percentage of total body surface affected by lesions.

    Time frame: Baseline and 9 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie results in a publication are available from the principal investigator (P.I.) on reasonable request. Access will be determined based on reasonable request and in accordance with the ethical approval

Time frame: The data will become available as following, starting 6 months after publication and end 5 years after publication.

Access criteria: The requests will be reviewed by the P.I. and the steering committee. Study plans on meta-analyses generating new knowledge on exercise in persons with rheumatic diseases will be approved.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 67 non-industry interventional studies with no phase under Arthritis, Psoriatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 43. This study's planned 23 months is below that.

Counting every sponsor, half of 72 studies reached it within 31 months; a quarter within 13 and three quarters within 44.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jan 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 20, 2026
StartActual
Jan 26, 2026was Feb 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 23, 2026
Start date
Feb 2, 2026→Jan 26, 2026 (actual)
Oct 23, 2026
Contact
No study contact listed any more: removed a•••@vgregion.se · •••1195; removed e•••@vgregion.se
Oct 23, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Sahlgrenska University hospital · Gothenburg, SwedenContact removed a•••@vgregion.se · •••1195Contact removed (no phone or email listed)
  • Skaraborgs sjukvård, Skövde · Skövde, SwedenContact removed d•••@vgregion.se
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Feb 2, 2026→Jan 26, 2026 (now actual)
    Contact No study contact listed any more: removed a•••@vgregion.se · •••1195; removed e•••@vgregion.se
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Sahlgrenska University hospital · Gothenburg, SwedenContact removed a•••@vgregion.se · •••1195Contact removed (no phone or email listed)
    • Skaraborgs sjukvård, Skövde · Skövde, SwedenContact removed d•••@vgregion.se
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07352696
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Jan 26, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Annelie Bilberg, Assoc. Prof.
principal investigator · Sahlgrenska University hospital, Gothenburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion